Open access · OA
via OpenAlex
Drug synergy as a strategy for compression of morbidity in a Caenorhabditis elegans model of Alzheimer’s disease
Emelyne Teo, Sheng Fong, Nicholas S. Tolwinski, Jan Gruber
GeroScience · 2020 · ▲ 16 citations
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1007/s11357-020-00169-1
- Canonical
- link ↗
- Fetched
- 2026-06-14 MST
Cite this
APA
Teo, E., Fong, S., Tolwinski, N.S., & Gruber, J. (2020). Drug synergy as a strategy for compression of morbidity in a Caenorhabditis elegans model of Alzheimer’s disease. <em>GeroScience</em>. https://doi.org/10.1007/s11357-020-00169-1
Vancouver
Teo E, Fong S, Tolwinski NS, Gruber J. Drug synergy as a strategy for compression of morbidity in a Caenorhabditis elegans model of Alzheimer’s disease. GeroScience. 2020. doi:10.1007/s11357-020-00169-1.
BibTeX
@article{emelyne2020Drugsy,
title = {Drug synergy as a strategy for compression of morbidity in a Caenorhabditis elegans model of Alzheimer’s disease},
author = {Emelyne Teo and Sheng Fong and Nicholas S. Tolwinski and Jan Gruber},
journal = {GeroScience},
year = {2020},
doi = {10.1007/s11357-020-00169-1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Research Square 2023
Preprint · CC-BY
Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease
Neurotherapeutics 2010
Open access · OA
Astrocytes in Alzheimer's Disease
Nature Medicine 2023
Preprint · OA
Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
Biogerontology 2015
Citation only
Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer’s disease
Ageing Research Reviews 2020
Preprint · OA
Defective mitophagy in Alzheimer’s disease
Cell 2016
Open access · OA